在乳腺癌细胞中,LncRNA Miat knockdown 增强了 pirarubicin 介导的抗癌敏感性
Peng Huang1, Hongyuan Cheng1, Jiahua Ji1
1Department of Experimental Pharmacology and Toxicology, School of Pharmaceutical Sciences, Jilin University, Changchun, China.
Environmental toxicology
|August 20, 2023
概括
击败长非编码RNAMiat (lncRNAMiat) 增强了乳腺癌中皮拉鲁比辛 (THP) 的敏感性. 这种方法通过抑制通道来降低细胞活力和迁移,提供了潜在的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 皮拉鲁比辛 (THP) 是一种关键的抗瘤药物,但其有效性通常因耐药性发展而受到限制.
- 了解THP抗性背后的分子机制对于改善癌症治疗结果至关重要.
研究的目的:
- 研究长非编码RNAMiat (lncRNAMiat) 在调节乳腺癌中THP敏感性的作用.
- 阐明 lncRNA Miat knockdown 增强 THP 疗效的机制.
主要方法:
- 利用CCK8,TUNEL,流细胞计,伤口愈合,Transwell测定和西斑检测来评估细胞活力,细胞亡和迁移.
- 测量离子 (Ca2+) 度和量化基因/蛋白质表达,使用RT-qPCR和西欧布洛特.
- 在4T1小鼠乳腺癌细胞中研究了Miat过度表达和淘汰的影响.
主要成果:
- 与正常乳腺上皮细胞 (HC11) 相比,4T1细胞的MIAT表达显著更高.
- THP治疗降低了4T1细胞中的Miat表达.
- 结合THP的Miat Knockdown,导致细胞活力降低,细胞亡增加,并抑制细胞迁移.
- 这些效应与4T1细胞内细胞内离子水平的降低相关.
结论:
- 米阿特 Knockdown 增强了 4T1 乳腺癌细胞中的 THP 敏感性.
- 该机制涉及通道的抑制,导致细胞活力和迁移减少.
- 准 lncRNA Miat 是克服乳腺癌中 THP 耐药性的潜在策略.
相关概念视频
01:22MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
02:15Experimental RNAi
6.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
01:23RNA Interference
26.1K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.1K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K